An observational study in Hemophilia A, sponsored by Boston Children's Hospital. Completed at 1 site in United States. Open to male participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2020-07-14.
Sponsored by Boston Children's Hospital · Observational
Abnormalities in the gene encoding Factor VIII (FVIII) results in hemophilia A, an X-linked recessive bleeding disorder with a prevalence of 1 in 5000 males. Hemophilia A patients are classified into 3 different categories based on residual FVIII activity compared to normal: mild (6-40%), moderate (1-5%) and severe (\<1%). This categorization correlates to some degree with bleeding phenotype, but does not completely define it. Some patients with hemophilia A bleed less often than others despite identical plasma FVIII levels. The cause(s) of this phenotype heterogeneity in hemophilia A remains largely unknown, despite a number of studies of possible factors.
Activated platelets, in addition to their role in primary hemostasis, play a major role in secondary hemostasis (coagulation) by providing a phospholipid surface to which coagulation factors bind. A role for platelets in the hemorrhagic propensity of hemophilia A has been suggested in the past, but only a small number of studies have been performed with limitations in assays performed and numbers of patients. The purpose of the present study is to determine whether platelet reactivity in severe hemophilia A patients is associated with past bleeding frequency and/or predicts future bleeding frequency.
866 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.
This study's enrollment of 36 is below the median of 80 across 314 observational studies indexed under Hemophilia A.
Browse Hemophilia A studies →Boston Children's Hospital is the lead sponsor of 598 studies on the registry; 151 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 18 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with severe hemophilia A who do not have inhibitors against FVIII and who have a bleeding history of at least 6 months.
Exclusion Criteria:
The percentage of coated platelets.
Time frame: 2 years
Platelet reactivity.
Time frame: 2 years
The number of procoagulant platelet-derived microparticles.
Time frame: 2 years
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boston Children's Hospital